Impax Asset Management Group plc Acquires 19,894 Shares of Gilead Sciences, Inc. $GILD

Key Points

• Impax Asset Management increased its stake in Gilead by 7.2%, buying 19,894 shares to hold 296,565 shares worth about $36.4 million after the quarter.
• Insiders, including CEO Daniel Patrick O'Day, sold shares recently (O'Day sold 10,000 shares at $144.79), with insiders offloading 178,640 shares worth $26.7 million in the last quarter and now owning just 0.30% of the company.
• Wall Street sentiment is broadly positive—multiple firms raised price targets and ratings (24 Buys vs. 4 Holds) with a consensus target of $157.35, while Gilead trades around $130.40 and recently set FY2026 EPS guidance of 8.45–8.85.

Impax Asset Management Group plc raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 7.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 296,565 shares of the biopharmaceutical company's stock after buying an additional 19,894 shares during the quarter. Impax Asset Management Group plc's holdings in Gilead Sciences were worth $36,400,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC grew its stake in shares of Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock valued at $1,326,000 after purchasing an additional 2,450 shares during the period. Bison Wealth LLC bought a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $215,000. Sivia Capital Partners LLC grew its stake in shares of Gilead Sciences by 16.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company's stock valued at $464,000 after purchasing an additional 602 shares during the period. Ieq Capital LLC grew its stake in shares of Gilead Sciences by 12.0% in the 2nd quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company's stock valued at $13,160,000 after purchasing an additional 12,705 shares during the period. Finally, Diversify Advisory Services LLC grew its holdings in shares of Gilead Sciences by 18.6% in the 2nd quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company's stock worth $516,000 after purchasing an additional 674 shares during the last quarter. Institutional investors own 83.67% of the company's stock.

Insider Transactions at Gilead Sciences

In other news, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction on Friday, February 27th. The stock was sold at an average price of $144.79, for a total value of $1,447,900.00. Following the transaction, the chief executive officer directly owned 642,308 shares in the company, valued at $92,999,775.32. This trade represents a 1.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Johanna Mercier sold 3,000 shares of the firm's stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total value of $422,880.00. Following the completion of the transaction, the insider owned 128,779 shares in the company, valued at $18,152,687.84. This represents a 2.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 178,640 shares of company stock worth $26,691,550 in the last quarter. 0.30% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on GILD. BMO Capital Markets upped their target price on shares of Gilead Sciences from $135.00 to $150.00 and gave the stock an "outperform" rating in a report on Monday, January 26th. Citigroup upped their target price on shares of Gilead Sciences from $156.00 to $165.00 and gave the stock a "buy" rating in a report on Monday, April 13th. Bank of America set a $162.00 target price on shares of Gilead Sciences and gave the stock a "buy" rating in a report on Wednesday, February 11th. Jefferies Financial Group began coverage on Gilead Sciences in a research report on Tuesday, March 10th. They set a "buy" rating and a $180.00 price target on the stock. Finally, JPMorgan Chase & Co. increased their price target on Gilead Sciences from $150.00 to $160.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 11th. Twenty-four analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $157.35.

Gilead Sciences Stock Down 2.4%

Shares of GILD opened at $130.40 on Friday. The firm has a market capitalization of $161.86 billion, a price-to-earnings ratio of 19.26, a PEG ratio of 1.76 and a beta of 0.39. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55. The business's fifty day moving average price is $142.44 and its two-hundred day moving average price is $132.02. Gilead Sciences, Inc. has a 52 week low of $93.37 and a 52 week high of $157.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating analysts' consensus estimates of $1.83 by $0.03. The firm had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business's quarterly revenue was up 4.7% compared to the same quarter last year. During the same period last year, the company earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, analysts predict that Gilead Sciences, Inc. will post 8.63 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 30th. Stockholders of record on Friday, March 13th were given a dividend of $0.82 per share. The ex-dividend date was Friday, March 13th. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.79. Gilead Sciences's dividend payout ratio is presently 48.45%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.